Home / Knowledge Centre /

Antibody-Drug Conjugates: Carbon-14 Labeling Requirements

The next blockbuster drug revenue streams are likely to come from a class of targeted therapies geared towards the treatment and management of chronic human disease states, especially cancer, and involve the use of antibody-drug conjugates (ADCs).
This article, published in Drug Development and Delivery magazine, May 2013, looks at carbon-14 labelling requirements for these types of drugs and their future development.

View Resource
Almac Logo

Almac API, Chemical Development, Analytical & Solid State Services

Almac Sciences provides integrated services from development to commercial scale of advanced intermediates and Active Pharmaceutical Ingredients (API).

We provide a range of services for small molecules (including highly potent) and peptides. We have a proven track record of saving time and cost through the integration of our services and application of innovative biocatalysis and technology solutions.

Learn More

We offer a full suite of analytical testing for a range of different product types including small molecules, peptides, biologics, conjugates, potent and controlled substances.

Our vast pool of scientific knowledge can help to overcome the analytical challenges that typically arise during drug development.

Learn More

Please complete this form to view the Article

This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies